Drug reference

Daunorubicin with cytarabine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 973

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Acute myeloid leukaemia ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature)

PDF page 973

Cautions

Wilson’s disease or other copper-related disorders (each vial contains 100 mg of copper gluconate, equivalent to 14 mg of elemental copper)

PDF page 973

Prescribing And Dispensing Information

Daunorubicin with cytarabine is available as a liposomal formulation. This is not interchangeable with other daunorubicin- or cytarabine-containing preparations; such preparations differ in their licensed indications, pharmacokinetics, dosage and administration.

PDF page 973

National Funding Access Decisions

NICE decisions ▶Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (December 2018) NICE TA552 Liposomal cytarabine–daunorubicin (Vyxeos ®) is recommended, within its marketing authorisation, as an option for untreated therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes in adults. It is Immune system and malignant disease recommended only if the manufacturer provides it according to the commercial arrangement. www.nice.org.uk/guidance/ta552 Scottish Medicines Consortium (SMC) decisions SMC No. SMC2130 The Scottish Medicines Consortium has advised (March 2019) that liposomal daunorubicin with cytarabine (Vyxeos ®) is accepted for use within NHS Scotland for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (AML) or AML with myelodysplasia-related changes. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

PDF page 973

Safety

Interactions

→Appendix 1: anthracyclines. cytarabine

PDF page 973

Hepatic Impairment

Manufacturer advises caution in severe impairment.

PDF page 973

Renal Impairment

Manufacturer advises caution in severe impairment.

PDF page 973

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion ▶Vyxeos (Jazz Pharmaceuticals UK) Daunorubicin 44 mg, Cytarabine 100 mg Vyxeos liposomal 44mg/100mg powder for concentrate for solution for infusion vials | 1 vial P £4,581.00 (Hospital only)

PDF page 973

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 973

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Daunorubicin with cytarabine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 973

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Acute myeloid leukaemia ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature)

PDF page 973

Cautions

Wilson’s disease or other copper-related disorders (each vial contains 100 mg of copper gluconate, equivalent to 14 mg of elemental copper)

PDF page 973

Prescribing And Dispensing Information

PDF page 973

National Funding Access Decisions

PDF page 973

Safety

Interactions

→Appendix 1: anthracyclines. cytarabine

PDF page 973

Hepatic Impairment

Manufacturer advises caution in severe impairment.

PDF page 973

Renal Impairment

Manufacturer advises caution in severe impairment.

PDF page 973

Dose and formulations

Medicinal Forms

PDF page 973

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 973

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.